Comparative Pharmacology
Head-to-head clinical analysis: OPTIMARK versus TESLASCAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: OPTIMARK versus TESLASCAN.
OPTIMARK vs TESLASCAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Gadolinium-based MRI contrast agent that increases signal intensity by shortening T1 relaxation time in tissues where it accumulates.
Teslascan is a manganese-based paramagnetic contrast agent that enhances T1-weighted magnetic resonance imaging (MRI). Manganese ions shorten the T1 relaxation time of protons, increasing signal intensity in tissues where it accumulates.
0.1 mmol/kg (0.2 mL/kg) intravenously as a single bolus injection; not to exceed 20 mL per dose.
0.1 mL/kg (0.1 mmol/kg) intravenous bolus injection.
None Documented
None Documented
Terminal elimination half-life is approximately 1.5–2 hours in patients with normal renal function. In patients with severely impaired renal function (GFR <30 mL/min), half-life is significantly prolonged (up to 20 hours).
Terminal elimination half-life is 6.2 hours in patients with normal renal function (CrCl > 60 mL/min). In patients with moderate renal impairment (CrCl 30-60 mL/min), half-life increases to 9.5 hours; in severe impairment (CrCl < 30 mL/min), half-life exceeds 15 hours.
Primarily renal excretion (glomerular filtration). >95% of the administered dose is eliminated unchanged in urine within 24 hours. Biliary/fecal elimination is negligible (<1%).
70% renal (unchanged drug), 30% fecal (biliary excretion).
Category C
Category C
MRI Contrast Agent
MRI Contrast Agent